XtalPi (HKG:2228) expects an attributable profit of 100 million yuan for the year 2025, compared with an attributable loss of 1.52 billion yuan a year prior, according to a Tuesday Hong Kong bourse filing.
This is reportedly the first instance of the pharmaceutical research firm recording a full-year profit.
The firm attributed the forecast to a 193% rise in revenue, an increase in net fair value gains on financial assets measured at fair value through profit or loss, and the absence of a fair value loss of convertible redeemable preferred shares as was seen in 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments